Background: Patients with chronic kidney disease (CKD) are at increased risk for cardiovascular events. Current guideline recommends intensive lipid-lowering therapy with statins. However, concerns about potential toxicity in patients with impaired renal function could have limited the widespread use of statins. Method: This retrospective study enrolled the patients who had CKD stage 2-5 from March to May 2010. All patients taking statins were divided into two groups according to the potency of statins: moderate (M; total cholesterol reduction is less than 30% from baseline) vs. intensive (I; total cholesterol reduction is more than 30% from baseline). During 1-year follow-up, safety and tolerance were monitored by clinical and laboratory parameters. Result: A total of 237 patients (155 patients in M group, 82 patients in I group) were enrolled. Serum creatinine level (4.6짹3.6 mg/dL in M group, 4.6짹3.9 mg/dL in I group; p=0.994) and the proportion of dialysis patients (23.2% in M group, 26.8% in I group; p=0.563) did not differ between groups. The most commonly used statin was atorvastatin in M group and rosuvastatin in I group. Although the incidence of adverse events was higher in I group than in M group, there was no statistical significance (3.9% in M group, 6.1% in I group; p =0.520). Conclusion: In patients with CKD, various statins can be used safely to modify dyslipidemia.